All News

The Company announces that it received notice today that the following Directors acquired the following number of ordinary shares in the Company at the following prices per share. Click here to read in full...

Read More

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that, based on its unaudited management accounts for the year ended 30 June 2019, the Company is trading in line with analyst expectations. The Company expects to publish its final audited results for the year ending 30 June 2019 during the...

Read More

Written by David Orrell As discussed in the last post, models have two functions – to describe, and to predict. In systems biology, and other areas of science, these are often conflated. We say a model is predictive, when really we mean it is descriptive. But prediction – from the Latin praedicere for “make known beforehand” – is not the same as just reproducing something that...

Read More

Physiomics signs agreement with Bicycle Therapeutics and Cancer Research UK Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has signed an agreement to work with Bicycle Therapeutics and Cancer Research UK.  The project is expected to be completed during this calendar year and will focus on the...

Read More

Physiomics signs agreement with Bicycle Therapeutics to support immune-oncology program Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has been awarded a contract by Bicycle Therapeutics plc (Nasdaq: BCYC) (“Bicycle”).  The project will focus on the mathematical computer modelling of interactions between tumour and Bicycle® compounds in...

Read More

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has appointed Strand Hanson Limited as its Nominated and Financial Adviser, with immediate effect. Hybridan LLP will continue to act as the Company’s sole broker.   Enquiries:   Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980   Strand Hanson Ltd (NOMAD) Richard Tulloch & James Dance +44...

Read More

Written by David Orrell.    The Virtual Tumour (“VT”) is the main program we use at Physiomics to optimise oncology treatments and predict the effects of drug combinations. This post is the first in a series that will describe the aims, motivations, and some of the history of the project – and gives a peek at the mathematics inside. Today’s topic: why we built the model. The VT,...

Read More
})(jQuery)